Payment overview · 2025
General Payments
$129,058.58
220 reported records · 15 companies
Healthcare provider profile · identity verified
Shailendra Singh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · ALLENTOWN, PA · NPI 1114213774
Verified facts
What the public records show
CMS Open Payments records show Shailendra Singh, M.D. received $129,058.58 in general payments during 2025 across 220 reported records.
Medtronic, Inc. accounted for 49.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$64,252.54 | 49.8% | 119 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $30,614.48 | 23.7% | 32 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $22,437.73 | 17.4% | 16 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $4,767.05 | 3.7% | 3 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $2,100.00 | 1.6% | 1 | 2025 |
| CathWorks, Inc. | Unresolved — no canonical attribution shown | $1,750.00 | 1.4% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $1,150.59 | 0.9% | 6 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $983.07 | 0.8% | 10 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $490.00 | 0.4% | 22 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $236.32 | 0.2% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $144.27 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $63.16 | 0.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.38 | 0.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.87 | 0.0% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $21.12 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $69,463.75 | 19 |
| Travel and Lodging | $32,249.67 | 72 |
| Consulting Fee | $22,068.50 | 11 |
| Food and Beverage | $5,276.66 | 118 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRANGIO Normalized: ffrangio |
Device | CathWorks, Inc., Medtronic, Inc. | $32,655.43 | 16 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $22,588.83 | 14 | 2025 |
Source payment records
|
|||||
| OEC Normalized: oec |
Device | GE HEALTHCARE | $17,426.70 | 11 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $8,947.18 | 5 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $5,636.19 | 4 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $4,767.05 | 3 | 2025 |
Source payment records
|
|||||
| Allia Normalized: allia |
Device | GE HEALTHCARE | $4,199.00 | 2 | 2025 |
Source payment records
|
|||||
| RESOLUTE ONYX Normalized: resolute onyx |
Device | Medtronic, Inc. | $3,037.77 | 10 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $1,840.89 | 33 | 2025 |
Source payment records
|
|||||
| OverStitch Endoscopic Suturing System Normalized: overstitch endoscopic suturing system |
Device | Boston Scientific Corporation | $1,185.10 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $1,150.59 | 6 | 2025 |
Source payment records
|
|||||
| Apollo ESG NXT System Normalized: apollo esg nxt system |
Device | Boston Scientific Corporation | $918.56 | 6 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $739.90 | 6 | 2025 |
Source payment records
|
|||||
| ONYX 18 Normalized: onyx 18 |
Device | Medtronic, Inc. | $537.35 | 2 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $230.39 | 3 | 2025 |
Source payment records
|
|||||
| Sterling Normalized: sterling |
Device | Boston Scientific Corporation | $213.06 | 2 | 2025 |
Source payment records
|
|||||
| R2P MISAGO Normalized: r2p misago |
Device | Terumo Medical Corporation | $187.85 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $144.27 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $63.16 | 2 | 2025 |
Source payment records
|
|||||
| GLIDESHEATH SLENDER Normalized: glidesheath slender |
Device | Terumo Medical Corporation | $48.47 | 2 | 2025 |
Source payment records
|
|||||
| OptiCross 35 Normalized: opticross 35 |
Device | Boston Scientific Corporation | $47.52 | 1 | 2025 |
Source payment records
|
|||||
| OPTITORQUE Normalized: optitorque |
Device | Terumo Medical Corporation | $39.80 | 1 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Systems Undivided Normalized: igt devices systems undivided |
Device | Philips North America LLC | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $19.07 | 2 | 2025 |
Source payment records
|
|||||
| Crosser IQ Normalized: crosser iq |
Device | Bard Peripheral Vascular, Inc. | $12.78 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $12.10 | 1 | 2025 |
Source payment records
|
|||||
| TR BAND Normalized: tr band |
Device | Terumo Medical Corporation | $8.67 | 1 | 2025 |
Source payment records
|
|||||
| SEISMIQ LITHOTRIP_PI Normalized: seismiq lithotrip pi |
Device | Boston Scientific Corporation | $6.15 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $5.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 230 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 179 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 56 |
| Eliquis | Apixaban | 145 | 40 |
| Lisinopril | Lisinopril | 110 | 32 |
| Losartan Potassium | Losartan Potassium | 89 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 88 | 34 |
| Ezetimibe | Ezetimibe | 77 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 16 |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Xarelto | Rivaroxaban | 42 | 11 |
| Carvedilol | Carvedilol | 40 | 15 |
| Furosemide | Furosemide | 39 | 15 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 18 |
| Mupirocin | Mupirocin | 22 | 21 |
| Atenolol | Atenolol | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129,058.58 · 220 records | Medtronic, Inc. | AVVIGO Guidance System, Allia, Apollo ESG NXT System, Bimzelx, COREVALVE EVOLUT R, Crosser IQ, FFRANGIO, Flexitouch Plus, GLIDESHEATH SLENDER, General - Therapies, HAWKONE, IGT Devices Systems Undivided, KENGREAL, LEQVIO, LUTONIX Drug Coated Balloon, NAVITOR, Nimbl, OEC, ONYX 18, ONYX FRONTIER, OPTITORQUE, OptiCross 35, OverStitch Endoscopic Suturing System, R2P MISAGO, RESOLUTE ONYX, Ranger, RotarexS 6 F x 135 cm, SEISMIQ LITHOTRIP_PI, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Sterling, TR BAND | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error